Quick Search 
Drugs of the Future
Register or sign in

Volume 47, Issue 6, June 2022, Pages 407-481
Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity.
Sperry, A.J., Hardy, J., Goldfaden, R., Hurst, A., Ashchi, A., Sutton, D., Sheikh-Ali, M., Huston, J., Choksi, R.
Drugs Fut 2022, 47(6): 407
Summary | Full Text: PDF 
Bispecific anti-PD-L1/CTLA-4 antibody, Cancer immunotherapy.
Qin, J., Shi, Z., Teng, Q-X., Bo, L., Han, C., Chen, Z.-S.
Drugs Fut 2022, 47(6): 419
Summary | Full Text: PDF 
 Lenadogene nolparvovec.
rAAV2 gene therapy vector encoding ND4, Treatment of Leber hereditary optic neuropathy.
Ferro Desideri, L., Traverso, C.E., Iester, M.
Drugs Fut 2022, 47(6): 429
Summary | Full Text: PDF 
 Tavokinogene telsaplasmid.
DNA-based interleukin-12 (IL-12), Gene therapy, Treatment of metastatic melanoma, Treatment of triple-negative breast cancer, Treatment of head and neck cancer.
Switzer, B., Puzanov, I.
Drugs Fut 2022, 47(6): 435
Summary | Full Text: PDF 
 Gene therapy in the fight against pediatric blood disorders: sickle cell disease and β-thalassemia.
Hu, W., Wang, B., Song, G., Wang, X., Wang, X.
Drugs Fut 2022, 47(6): 443
Summary | Full Text: PDF 
 Pipeline on the Move.
Fernandez Bertolin, L.
Drugs Fut 2022, 47(6): 457
Full Text: PDF 
 American Academy of Neurology (AAN) – 74th Annual Meeting: The Great Neuro Reunion. Seattle – April 2-7, 2022.
Polychrones, J.
Drugs Fut 2022, 47(6): 471
Summary | Full Text: PDF 

© 2022 Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences